The global digital biomarkers market is expected to witness a CAGR of 41.25% during the forecast period. The growth of digital biomarkers is attributed to the rapid adoption of smartphones, wearable devices, biosensors, and innovation of high-speed networks, and connectivity solutions. The increasing cases of diabetes, BP, cardiovascular diseases, neurological disorders will propel the growth of the digital biosensors market globally as it is used for monitoring, diagnostic and prognostic purposes.

Furthermore, the rising number of synergistic associations among stakeholders, R&D of the advanced digital markers, increasing number of industry players, favorable government initiatives, fast approval from FDA, multiple product launches, are significantly aiding the growth of the global digital biomarkers market. Moreover, the data generated from biomarkers are validated via clinical trial programs.

Download Free Sample Copy Of Research Report: https://www.vynzresearch.com/healthcare/digital-biomarkers-market/request-sample

Digital solutions for biomarkers is the modernized platform to generate, collect and track healthcare data. Healthcare professionals are using the digital biomarkers to facilitate the successful screening and diagnosis of COVID-19 patients remotely.

Based on the system components, the global digital biomarkers are segmented into data collection tools and data integration systems. The data collection tools are further segmented into digital platforms, mobile apps, desktop-based software, wearable, and biosensors. Moreover, biosensors also hold a significant share in the digital biosensors market owing to its ability to check the health status, onset, and development of diseases and monitors health condition by using a non-invasive approach in medical research.

Europe is anticipated to have a high CAGR during the forecast period 2021-2027 owing to the rising standardization and collaboration among the stakeholders in the pharmaceutical industry. Moreover, the rising adoption of telehealth services, strong healthcare infrastructure, and rise in spending by the government for development in medical research will fuel the growth in the region.

Some of the major players in the global digital biomarkers market include AliveCor Labs, Eli Lilly and Company, Biogen, Novartis AG, Fitbit LLC, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Pfizer Inc., and Takeda Pharmaceutical Company Limited.

Source: VynZ Research